Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

CA Dinarello - Blood, The Journal of the American Society of …, 2011 - ashpublications.org
… The effect of IL-1 blockade appears to be superior to that of steroids and result in prolonged
periods without flares. Although some studies report that urate crystals directly activate the …

Targeting interleukin-1 in heart disease

BW Van Tassell, S Toldo, E Mezzaroma, A Abbate - Circulation, 2013 - Am Heart Assoc
… blockers that have been developed recently have provided opportunities to validate the
effect IL-1 blockade in preclinical models. The use of a recombinant chimeric protein composed …

Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center …

B Van Tassell, V Mihalick, G Thomas… - Journal of Translational …, 2022 - Springer
… IL-1 blockade with anakinra has been shown to prevent adverse cardiac remodeling and
HF in animal models of acute myocardial infarction (AMI) and reduce the incidence of HF in …

Efficacy of topical blockade of interleukin-1 in experimental dry eye disease

A Okanobo, SK Chauhan, MH Dastjerdi… - American journal of …, 2012 - Elsevier
… The current study demonstrates the beneficial effect of IL-1 blockade via the topical application
of IL-1Ra in treating the ocular signs and reversing the inflammatory changes associated …

The combination of tumor necrosis factor α blockade with interleukin1 and interleukin‐17 blockade is more effective for controlling synovial inflammation and bone …

M Chabaud, P Miossec - … & Rheumatism: Official Journal of the …, 2001 - Wiley Online Library
Objective Anti–tumor necrosis factor α (anti‐TNFα) therapy has shown efficacy in the
treatment of rheumatoid arthritis (RA). Since interleukin1 (IL‐1), TNFα, and IL‐17 have many …

Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III …

B Shakoory, JA Carcillo, WW Chatham… - Critical care …, 2016 - journals.lww.com
… features may benefit from interleukin-1 receptor blockade. … In this subgroup analysis,
interleukin-1 receptor blockade was … be undertaken to confirm the role of interleukin-1 blockage. …

Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

SH Lan, CK Hsu, SP Chang, LC Lu, CC Lai - Annals of Medicine, 2023 - Taylor & Francis
… included in this meta-analysis ( Figure 1 and Supplementary Appendix 1). Overall, this meta-…
-1 blockade group and 732 in the control group. Among the patients receiving IL-1 blockade

Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism

G Kaplanski, C Farnarier, S Kaplanski, R Porat… - 1994 - ashpublications.org
interleukin-8 (IL-8) appears to be involved. We asked whether adherence of cells bearing a
membrane-form of interleukin 1 (IL-1) … Blockade of IL-1 receptors on PBMC did not affect the …

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes

CM Larsen, M Faulenbach, A Vaag, JA Ehses… - Diabetes …, 2009 - Am Diabetes Assoc
… The sustained reduction of CRP and IL-6 levels at 39 weeks after anakinra withdrawal is
notable and indicates that transient IL-1 blockade is capable of inducing not only a metabolic …

Interleukin-1 blockade in acute myocardial infarction and heart failure: getting closer and closer

S Toldo, BW Van Tassell, A Abbate - Basic to Translational Science, 2017 - jacc.org
… (1). Tissue injury stimulates the formation of the inflammasome and the production of interleukin
(IL… and systemic inflammatory response, also known as the “fever molecule”(4)(Figure 1). …